Low testosterone is linked to heart disease, metabolic syndrome, and early death. Here is what the cardiovascular evidence actually shows, and who carries real risk.
Low testosterone is linked to heart disease, metabolic syndrome, and early death. Here is what the cardiovascular evidence actually shows, and who carries real risk.
Yes, and the evidence is stronger than most men realize. Low testosterone, the clinical term is hypogonadism (when your testes don't produce enough of the hormone), is independently associated with higher rates of cardiovascular disease, metabolic syndrome, and early death in large population studies. This is not a wellness claim. It shows up in hard outcomes data across multiple research designs.
Testosterone does not work in isolation. It interacts with blood sugar regulation, fat distribution, blood vessel flexibility, and the heart muscle itself. A 2025 meta-analysis published in Arquivos Brasileiros de Cardiologia found that "low testosterone levels are modestly associated with an increased risk of HF in men (HR 1.10, 95% CI: 1.03–1.17)" across a pooled sample of 233,474 participants [6]. That association is modest, but it is directionally consistent with what the mechanistic studies show.
Higher cardiovascular risk markers travel alongside low testosterone consistently. Research from NHANES data found that men with higher cardiovascular health scores, covering diet, activity, blood pressure, and metabolic function, had substantially lower odds of testosterone deficiency. Each 10-point increase in the cardiovascular health composite score corresponded to a 21% lower odds of testosterone deficiency. The bidirectional story is real: low testosterone worsens metabolic health, and poor metabolic health suppresses testosterone further.
What "low testosterone" means on a lab report is only part of the picture. Total testosterone measures all circulating hormone, but a large fraction is bound to a protein called SHBG (sex hormone-binding globulin), which acts like a carrier molecule that keeps testosterone locked up and unavailable. Only the free, unbound portion actually reaches your cells and does anything useful. Understanding both numbers matters before drawing any conclusions about your cardiovascular risk.
For a fuller guide to reading these values in context, the breakdown at how to read your hormone lab report walks through each marker step by step.
Testosterone reaches the cardiovascular system through at least three distinct pathways: it shapes how your body handles blood sugar and fat, it regulates the tone and flexibility of your arteries, and it influences the electrical timing of your heartbeat. Each pathway has a measurable consequence you can feel or track on a lab report.
The endothelium is the thin cellular lining of every blood vessel in your body. Think of it as a non-stick coating that keeps blood flowing smoothly and prevents plaque from sticking to artery walls. When testosterone is low, that coating stops working as well.
A 2025 study published in the American Journal of Physiology measured brachial artery flow-mediated dilation (FMD), a standard test of endothelial function, in 60 men divided by testosterone status. Middle-aged men with low testosterone had an FMD of 4.0%, compared with 5.7% in age-matched men with normal testosterone and 7.3% in young men [12]. Men with low testosterone also had significantly higher plasma endothelin-1, a potent vasoconstrictor (a molecule that tightens blood vessels), and that higher endothelin-1 level was inversely correlated with endothelial function [12]. In plain terms: low testosterone appears to raise circulating levels of a substance that squeezes your arteries shut, which is one mechanism by which chronically low testosterone accelerates arterial aging.
Earlier research in men with end-stage kidney disease found that testosterone levels were negatively correlated with carotid artery intima-media thickness (a direct measure of plaque buildup) and positively correlated with endothelium-dependent vasodilation. Men with androgen deficiency in that cohort had significantly greater carotid wall thickening and reduced arterial responsiveness compared to those without deficiency.
Studies in younger men with idiopathic hypogonadotropic hypogonadism similarly found a negative correlation between total testosterone and carotid intima-media thickness. The consistency of these findings across very different populations, from young men with congenital hormone deficiency to older men with kidney disease, makes the endothelial angle one of the better-established mechanisms connecting low testosterone to cardiovascular risk.
A 2022 review of cardiovascular complications in Klinefelter syndrome (a genetic condition that causes primary hypogonadism) documented subclinical atherosclerosis and endothelial dysfunction as characteristic features of the condition, consistent with the broader literature linking testosterone deficiency to early-stage arterial disease.
Insulin resistance means your cells stop responding well to insulin, the hormone that moves sugar out of your blood. Fat accumulates, blood sugar climbs, and the heart works against a progressively hostile metabolic environment. Men with congenital hypogonadotropic hypogonadism have elevated visceral adiposity index (a composite marker of metabolic risk) and higher triglyceride-to-HDL ratios compared to healthy peers, both of which are independent predictors of cardiovascular risk.
A large retrospective cohort study following 4,307 men over 12 months of testosterone deficiency treatment reported a relative reduction in triglycerides of roughly 20% and a relative reduction in HbA1c (a three-month average of blood sugar control) of roughly 4.5% [8]. Men who started with elevated triglycerides saw even sharper drops [8]. Treating low testosterone may move two important metabolic markers in the right direction, though this was a non-randomized study and lifestyle changes contributed to the improvements.
Ultra-processed food intake adds an additional layer: a cross-sectional analysis of over 72,000 UK Biobank participants found that a UPF-associated metabolomic signature was negatively associated with both SHBG and testosterone, suggesting that diet quality affects androgen status partly through metabolite-level changes [11].
The QT interval is the electrical pause between heartbeats. When it stretches too long, the heart can tip into a dangerous arrhythmia called torsades de pointes (roughly: "twisting of the points"), a rapid, disorganized rhythm. A 2025 translational study published in JACC Clinical Electrophysiology enrolled 68 patients who developed torsades de pointes over 13 years. Compared to control subjects, male TdP patients had significantly reduced testosterone levels, and within the cohort, lower testosterone in men was associated with worse short-term arrhythmia outcomes [7]. In laboratory experiments, reproducing the sex-hormone profile of male TdP patients prolonged action potential duration in cardiomyocytes (heart muscle cells), and adding testosterone back reversed that effect [7]. The implication is that testosterone exerts a direct, measurable protective effect on cardiac electrical stability in men.
Beyond the endothelium, testosterone acts on vascular smooth muscle to promote vasodilation (relaxing and widening blood vessels). A 2013 review in the Journal of Endocrinology described testosterone as "a vasoactive hormone" that acts partly through L-type calcium channel blockade and potassium channel activation in vascular smooth muscle, increasing coronary artery diameter and flow in men with chronic stable angina and reducing peripheral vascular resistance in heart failure. The mechanism is not purely endothelial; testosterone also directly tells arteries to relax.
| Pathway | What changes in low testosterone | What may improve with treatment |
|---|---|---|
| Endothelial function | Higher endothelin-1, reduced FMD, greater carotid IMT | Improved arterial responsiveness [12] |
| Metabolic markers | Elevated triglycerides, higher HbA1c, insulin resistance | Triglycerides down ~20%, HbA1c down ~4.5% at 12 months [8] |
| Cardiac electrical | Prolonged QT interval, higher TdP susceptibility | Testosterone shortens action potential duration [7] |
| Vascular tone | Increased peripheral resistance, reduced coronary flow | Vasodilation via calcium and potassium channel effects |
| Atherosclerosis | Greater plaque burden, elevated visceral adiposity | Visceral adiposity index lower in eugonadal men |
The TRAVERSE trial gave clinicians the clearest cardiovascular safety data on TRT available, and the headline result was reassuring: testosterone did not increase the risk of major adverse cardiac events compared to placebo in men with hypogonadism and established or high cardiovascular risk [15].
MACE, which stands for major adverse cardiovascular events, is the composite outcome researchers use to capture the most serious cardiac harms: heart attack, stroke, and cardiovascular death. A 2024 evidence synthesis and meta-analysis of 35 trials including 5,601 participants found "no difference between the testosterone replacement therapy group (120/1601, 7.5%) and placebo group (110/1519, 7.2%) in the incidence of cardiovascular and/or cerebrovascular events (13 studies, odds ratio 1.07, 95% confidence interval 0.81 to 1.42)" [15]. That is a meaningful finding: in the broadest synthesis of controlled trial data available, TRT in hypogonadal men did not drive up serious cardiac events.
The reassurance on MACE does not end the conversation. Several signals require active monitoring on TRT, and understanding the biological mechanisms behind them is important.
Atrial fibrillation remains an area of ongoing concern. The 2025 JACC electrophysiology study identified sex-hormone imbalances, specifically altered estradiol-to-testosterone ratios, as contributors to cardiac electrical remodeling and arrhythmia susceptibility [7]. Testosterone is converted to estradiol through a process called aromatization (the enzyme aromatase performs this conversion), and shifts in that balance during TRT may affect atrial conduction in susceptible men. This is not fully characterized in large randomized trials, but the electrophysiological mechanism is established at the cellular level [7].
NOT SURE WHERE TO START?
Take our 2-minute hormone & metabolism quiz to see exactly where you stand. Or skip ahead — a $49 lab panel gives you the numbers, a free hormone screen gives you a plan.
Polycythemia refers to an excess of red blood cells, a well-documented consequence of TRT. The same 2024 meta-analysis noted that hematocrit (the proportion of blood volume made up of red blood cells) was affected by TRT [15]. When hematocrit climbs too high, blood thickens and becomes harder to pump, raising the risk of clotting events including venous thromboembolism and, in some cases, contributing to stroke risk. This is a prothrombotic state (a condition that makes clotting more likely) and represents the clearest mechanism by which TRT can shift cardiovascular risk upward when not monitored properly. Hematocrit monitoring is a standard part of well-managed TRT protocols, and a detailed breakdown of managing that variable is at TRT and high hematocrit.
The following signals and their management checkpoints are worth knowing before starting therapy:
TRAVERSE enrolled men who already had cardiovascular disease or carried high cardiovascular risk. That context shapes every conclusion. A healthy man in his early forties starting TRT does not carry the same baseline risk profile as the average TRAVERSE participant. The trial tells us something important about safety in a high-risk population; it tells us less about men further from that profile.
| Outcome | Finding from controlled trial evidence |
|---|---|
| MACE (heart attack, stroke, CV death) | No significant difference vs. placebo [15] |
| Atrial fibrillation | Electrophysiological risk linked to sex-hormone balance [7] |
| Hematocrit elevation | Documented; requires monitoring [15] |
| Triglycerides | Reduced ~20% over 12 months in observational cohort [8] |
| HbA1c | Reduced ~4.5% over 12 months in observational cohort [8] |
| HDL cholesterol | Reduced ~9% over 12 months [8] |
For men with confirmed testosterone deficiency, treating that deficiency does appear to shift several cardiometabolic markers in a favorable direction, though the picture is uneven across different lab values and the evidence remains largely observational.
The 2025 retrospective cohort study of 4,307 men tracked key metabolic markers across 12 months of testosterone deficiency treatment. Triglycerides fell by roughly 20% on average, and HbA1c dropped by about 4.5% [8]. Men who started with the highest triglyceride levels saw the largest reductions, suggesting those with the worst metabolic baseline had the most to gain [8]. The triglyceride-to-HDL ratio, a practical marker of insulin resistance and atherosclerosis risk, also improved substantially in men with elevated baseline values [8].
HDL, the so-called "good cholesterol" that helps clear fat from artery walls, told a different story in that same cohort. Average HDL levels fell by roughly 9% over 12 months [8]. Whether this represents a meaningful cardiovascular concern or a byproduct of broader metabolic remodeling remains debated. LDL (the cholesterol most associated with artery-clogging plaque) did not change significantly [8].
The connection between low testosterone and heart failure risk is biologically plausible. Testosterone supports heart-muscle energy production, and the meta-analysis of 233,474 participants found a modest but statistically significant association between lower testosterone and incident heart failure in men [6]. The authors note, however, that "the heterogeneity in study designs and population characteristics, combined with the weak associations observed, underscores the need for further rigorous investigation" [6]. The data here are real but not strong enough to anchor firm clinical conclusions without more randomized trial evidence.
For men with existing obesity or metabolic syndrome, the obesity-low-testosterone relationship adds further complexity to interpreting any single marker in isolation.
Not every man on TRT carries the same risk profile. Most healthy hypogonadal men tolerate therapy well, but a subset needs closer watching, and a smaller group needs specialist clearance before the first dose.
A prior heart attack, uncontrolled heart failure, or a recent stroke puts a man in a higher-stakes category. Men with pre-existing atrial fibrillation or electrical conduction abnormalities deserve particular attention given the cardiac electrophysiology findings discussed earlier [7]. Men with untreated or severe obstructive sleep apnea carry compounding cardiovascular strain through sympathetic nervous system overactivation and oxidative stress [1], and TRT can worsen airway tone during sleep, so baseline apnea screening matters.
A 2024 review of testosterone therapy in functional hypogonadism noted that recent randomized controlled trials and meta-analyses have demonstrated "safe long-term outcomes regarding prostatic and cardiovascular health, together with decreases in all-cause mortality and improvements in various domains, including sexual function, body composition, physical strength, bone density, and hematopoiesis". That summary applies to men receiving appropriately monitored therapy. The key phrase is appropriately monitored.
Testosterone tells bone marrow to produce more red blood cells, which carries oxygen to your tissues. A modest increase is fine and can even improve exercise tolerance. Too many red blood cells, however, and your blood thickens into something closer to syrup, placing extra strain on the heart and raising clotting risk. This polycythemia risk is the most actionable cardiovascular concern for most men on TRT. Monitoring hematocrit at baseline, then at 6–12 weeks, and at each follow-up thereafter, is not optional. It is the primary safety lever that separates well-managed TRT from poorly managed TRT.
For the full picture of fertility considerations alongside cardiac risk management, hCG in a TRT protocol covers how this fits into a well-structured protocol.
A conversation with your clinician should start well before any prescription is written. The baseline lab panel tells you whether therapy is appropriate, flags risks that need monitoring, and gives you a real number to compare against twelve months later.
Total testosterone alone misses too much. SHBG can render a normal total testosterone reading functionally low. Free testosterone, SHBG, LH, FSH, estradiol, hematocrit, HbA1c, a full lipid panel including apolipoprotein B (research shows an inverse correlation between testosterone and apoB levels, a cardiovascular risk marker), and PSA together give your clinician a complete picture. For a plain-language walkthrough of what each number means, understanding your hormone lab report is a useful starting point.
Longitudinal tracking of cardiometabolic markers during treatment matters. The 2025 retrospective cohort study of 4,307 men on TRT found significant changes in HDL, HbA1c, and triglycerides across twelve months [8]. Those numbers shifted, for better and worse, and only a monitoring schedule catches the direction early.
| Checkpoint | Key markers to review |
|---|---|
| Baseline (before starting) | Total T, free T, SHBG, LH, FSH, estradiol, hematocrit, HbA1c, lipid panel including apoB, PSA |
| 6–12 weeks | Hematocrit, total T, free T, blood pressure |
| 6 months | Full repeat of baseline panel |
| Annually | All of the above plus cardiovascular symptom review |
What to expect in your first 90 days on TRT covers the early monitoring window in more detail. Physician-supervised TRT with a structured follow-up schedule is what separates a well-managed protocol from one that creates new problems.
Sleep, nutrition, fitness, and hormones are the big dials. Before attributing every cardiovascular marker to testosterone, get those foundational variables reviewed, because the evidence consistently shows they interact. Low testosterone often arrives alongside poor sleep, metabolic dysfunction, and sedentary habits, and the honest clinical question is always which came first and which to address first. The answer is usually: all of them, in parallel, with numbers to track progress on each one.
Yes. Large population studies consistently show that low testosterone (hypogonadism) is associated with higher rates of cardiovascular disease, metabolic syndrome, and early death. A 2025 meta-analysis of 233,474 participants found low testosterone modestly associated with increased heart failure risk. However, the relationship is complex. Testosterone interacts with blood sugar regulation, fat distribution, blood vessel function, and heart muscle health, so low testosterone doesn't work in isolation. The connection between the hormone and cardiovascular risk is real and well-documented across multiple research designs.
Testosterone affects the cardiovascular system through at least three distinct pathways. First, it influences how your body handles blood sugar and fat. Second, it regulates the flexibility and tone of your arteries. Third, it controls the electrical timing of your heartbeat. When testosterone is low, the inner lining of blood vessels (the endothelium) stops working as well, which means your arteries become stiffer and less responsive. At the same time, substances that tighten blood vessels increase in circulation, restricting blood flow.
The TRAVERSE trial, the largest randomized controlled trial on this question, found testosterone replacement therapy did not increase the risk of major adverse cardiac events (heart attack, stroke, or cardiovascular death) compared to placebo in men with low testosterone and existing or high cardiovascular risk. However, safety requires active monitoring. Testosterone can elevate hematocrit (red blood cell count), which thickens blood and raises clotting risk. It may also affect atrial electrical activity in susceptible men. Hematocrit monitoring at baseline and 6-12 weeks is essential for safe therapy.
In a 12-month observational study of 4,307 men receiving testosterone deficiency treatment, triglycerides dropped approximately 20% and HbA1c (a measure of average blood sugar control) fell about 4.5%. Men who started with the highest triglyceride levels saw the largest improvements. The triglyceride-to-HDL ratio, which reflects insulin resistance and artery disease risk, also improved significantly in those with elevated baseline values. These are observational findings, so lifestyle changes alongside treatment likely contributed to the improvements.
Before starting, your clinician should measure total testosterone, free testosterone, SHBG, LH, FSH, estradiol, hematocrit, blood sugar, lipid panel, and PSA. After starting, hematocrit and hormone levels need checking at 6-12 weeks, then a full repeat of your baseline panel at 6 months, and annually thereafter. Blood pressure should be confirmed stable at baseline and rechecked at follow-up. This monitoring schedule is not optional. It's the primary safety mechanism that separates well-managed therapy from therapy that creates new problems.
Take our 2-minute hormone & metabolism quiz to see exactly where you stand — or jump straight to labs or a free screen with our team.